• Home/
  • News articles
Enactment of the Narcotic Drugs Amendment (Medicinal Cannabis) Act 2021
7 July 2021
The Amendment Act provides for amendments to the Narcotic Drugs Act 1967 to support an innovative Australian medicinal cannabis industry for the benefit of Australian patients.
Introduction of the Narcotic Drugs Amendment (Medicinal Cannabis) Bill 2021
4 February 2021
Introduction of the Narcotic Drugs Amendment (Medicinal Cannabis) Bill 2021
Commission on Narcotic Drugs votes on recommendations for cannabis and cannabis related substances
10 December 2020
On 2 December 2020, Australia voted at the Commission on Narcotic Drugs on six recommendations concerning the scheduling of cannabis and cannabis related substances
Medicinal cannabis permit reform consultation
13 November 2020
The ODC is seeking comments on a review of the structure, design and administrative processes relating to medicinal cannabis related permits
Webinar: Kava Pilot Phase 2 design (easing the restrictions on the commercial importation of kava)
10 November 2020
Webinar presentation has been added
Commencement of fees and charges for cannabis-related manufacture
2 November 2020
Cost recovery arrangements for cannabis-related manufacture licences and permits commenced on 1 November 2020.
Introduction of fees and charges for cannabis-related manufacture
6 October 2020
From 1 November 2020, subject to formal approval from the Federal Executive Council, cost recovery arrangements will be extended to cannabis-related manufacture licences and permits under the Medicinal Cannabis Scheme.
Reforms to Medicinal Cannabis Scheme Fees and Charges
27 July 2020
Changes to fees and charges related to the Medicinal Cannabis Scheme under the Narcotic Drugs Act 1967 commenced on 15 July 2020
Australian Government proposes strengthening its stance against e-cigarettes containing vaporiser nicotine
29 June 2020

From 1 January 2021, proposed regulations would prohibit the importation of e-cigarettes containing vaporiser nicotine.

Consultation: Medicinal Cannabis Cost Recovery Framework
13 March 2020

The Office of Drug Control (ODC) is seeking comments from interested parties on the proposed Medicinal Cannabis Cost Recovery Framework. Closing date: 20 March 2020